Process for the preparation of enantiomerically pure .beta.-D-(-)-dioxolane-nucleosides
US5179104A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 5, 1990 |
| Grant date | Jan 12, 1993 |
| Priority date | — |
| Expiry date | Dec 5, 2010 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An asymmetric process for the preparation of enantiomerically pure .beta.-D-(-)-dioxolane-nucleosides. The enantiomerically pure dioxolane nucleosides are active HIV agents, that are significantly more effective than the prior prepared racemic mixtures of the nucleosides. The anti-viral activity of the compounds is surprising in light of the generally accepted theory that moieties in the endo conformation, including these dioxolanes, are not effective antiviral agents. The toxicity of the enantiomerically pure dioxolane nucleosides is lower that that of the racemic mixture of the nucleosides, because the nonnaturally occurring .alpha.-isomer is not included. The product can be used as a research tool to study the inhibition of HIV in vitro or can be administered in a pharmaceutical composition to inhibit the growth of HIV in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.